Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model Cixutumumab - ...

MedChemExpress - Model Cixutumumab - 947687-12-9

Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer[1].

Cixutumumab

MCE China：Cixutumumab

Brand：MedChemExpress (MCE)

Cat. No.HY-P99189

CAS：947687-12-9

Synonyms：IMC-A12; NSC742460

Purity：99.63%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping：Shipping with dry ice.

Description：Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

In Vitro：Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells[1].

In Vivo：Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels[1].

IC50 & Target：IGF-1R[1]. In Vitro Cixutumumab (IMC-A12) (0.01-100 nM; 96 h) exhibits at least 50% growth inhibition in CHLA-9, TC-71and Rh41 cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Cixutumumab Related Antibodies Cell Viability Assay[1] Cell Line: CHLA-9, TC-71, Rh41 cells

Species：Human

Isotype：Human IgG1 lambda1

Recommend Isotype Controls：Human IgG1 lambda1, Isotype Control

References：

[1]. Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。